News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
898,145 Results
Type
Article (89674)
Company Profile (639)
Press Release (807808)
Multimedia
Podcasts (283)
Webinars (44)
Section
Business (267510)
Career Advice (4176)
Deals (40162)
Drug Delivery (246)
Drug Development (92150)
Employer Resources (212)
FDA (18737)
Job Trends (17562)
News (399631)
Policy (40038)
Tag
2025 Best Places to Work (25)
2026 Best Places to Work (39)
2027 BioCapital Standard (5)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (13)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (7)
2027 Genetown Elite (2)
2027 Genetown Standard (6)
2027 NextGen (10)
2027 Pharm Country Digital (4)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
40 Under 40 (4)
Academia (3112)
Academic (2)
Accelerated approval (76)
ADA (54)
Adcomms (44)
Allergies (237)
Alliances (57000)
ALS (292)
Alzheimer's disease (2149)
Antibody-drug conjugate (ADC) (778)
Approvals (19333)
Artificial intelligence (1147)
ASCO (350)
Autoimmune disease (537)
Automation (84)
Bankruptcy (414)
Belgium (45)
Best Places to Work (12636)
BIO (84)
Biologics (118)
BIOSECURE Act (23)
Biosimilars (308)
BioSpace Insights (271)
Biotechnology (340)
Bispecific (60)
Bladder cancer (253)
Brain cancer (104)
Breast cancer (980)
Cancer (8061)
Cardiovascular disease (684)
Career advice (3638)
Career pathing (65)
CAR-T (465)
CDC (82)
CDMO (236)
Celiac Disease (7)
Cell-line development (2)
Cell therapy (1279)
Cervical cancer (67)
Clinical research (81240)
Collaboration (2893)
Commercialization (76)
Company closure (10)
Compensation (1937)
Complete response letters (128)
COVID-19 (3089)
CRISPR (155)
CRO (8)
C-suite (1712)
Cystic fibrosis (182)
Data (11173)
Decentralized trials (4)
Denatured (112)
Depression (230)
Dermatology (207)
Diabetes (855)
Diagnostics (7948)
Digital health (85)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (565)
Drug pricing (255)
Drug shortages (41)
Duchenne muscular dystrophy (388)
Earnings (104810)
Editorial (85)
Employer branding (27)
Employer resources (184)
ESMO (441)
Events (141991)
Executive appointments (1385)
Eye disease (28)
FDA (23866)
Fibrodysplasia Ossificans Progressiva (17)
Fragile X (6)
Friedreich's ataxia (29)
Frontotemporal dementia (43)
Funding (2380)
Gene editing (323)
Generative AI (116)
Gene therapy (988)
GLP-1 (1416)
Government (5635)
Grass and pollen (8)
Guidances (446)
Healthcare (21523)
Hematology (236)
HIV (128)
Huntington's disease (93)
Idiopathic pulmonary fibrosis (16)
IgA nephropathy (155)
Immunology and inflammation (431)
Immuno-oncology (166)
Indications (298)
Infectious disease (3551)
Inflammatory bowel disease (285)
Inflation Reduction Act (17)
Influenza (168)
Intellectual property (389)
Interviews (830)
IPO (18072)
IRA (61)
Job creations (5211)
Job search strategy (2882)
JPM (73)
Kidney cancer (32)
Kidney disease (182)
Labor market (152)
Layoffs (733)
Leadership (70)
Legal (10180)
Licensing (130)
Liver cancer (121)
Longevity (58)
Lung cancer (1110)
Lung diease (27)
Lymphoma (566)
Machine learning (78)
Management (72)
Manufacturing (1660)
Marketing (41)
MASH (260)
Medical affairs (5)
Medical device (15486)
Medtech (15823)
Mergers & acquisitions (23653)
Metabolic disorders (2175)
Middle East (2)
mRNA (344)
Multiple sclerosis (262)
Multispecific (6)
NASH (24)
Netherlands (40)
Neurodegenerative disease (637)
Neuropsychiatric disorders (155)
Neuroscience (4367)
Neurotech (4)
NextGen: Class of 2026 (7718)
Non-profit (5176)
Now hiring (101)
Obesity (1027)
Opinion (410)
Ovarian cancer (301)
Pain (352)
Pancreatic cancer (459)
Parkinson's disease (495)
Partnered (53)
Patents (815)
Patient advocacy (8)
Patient recruitment (988)
Patient selection (117)
Peanut (81)
People (69163)
Peptides (44)
Pharmaceutical (83)
Pharmacy benefit managers (43)
Phase 1 (25054)
Phase 2 (35288)
Phase 3 (26600)
Pipeline (14670)
Policy (435)
Postmarket research (3561)
Preclinical (11210)
Press Release (74)
Prostate cancer (413)
Psychedelics (104)
Radioligand (3)
Radiopharmaceuticals (449)
Rare diseases (1615)
Real estate (7479)
Recruiting (84)
Regenerative medicine (38)
Regulatory (31902)
Reports (104)
Research institute (2823)
Resumes & cover letters (657)
Rett syndrome (60)
RNA editing (39)
RSV (107)
Saudi Arabia (1)
Schizophrenia (231)
Series A (410)
Series B (285)
Service/supplier (17)
Sickle cell disease (152)
Special edition (38)
Spinal muscular atrophy (201)
Sponsored (61)
Startups (4405)
State (2)
Stem cells (8)
Stomach cancer (24)
Substance use disorders (23)
Supply chain (173)
Switzerland (25)
Tariffs (108)
Tax incentives (2)
The Weekly (168)
Vaccines (1447)
Venture capital (185)
Weight loss (683)
Wet AMD (7)
Women's health (190)
Women in leadership (1)
Worklife (28)
Date
Today (251)
Last 7 days (1033)
Last 30 days (4016)
Last 365 days (34108)
2026 (30774)
2025 (33214)
2024 (37866)
2023 (42564)
2022 (53927)
2021 (58720)
2020 (57662)
2019 (51334)
2018 (39119)
2017 (37186)
2016 (38329)
2015 (44431)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1310)
Alabama (118)
Alaska (7)
Arizona (493)
Arkansas (17)
Asia (53208)
Australia (9370)
California (17375)
Canada (4780)
China (2069)
Colorado (772)
Connecticut (776)
Delaware (548)
Europe (122863)
Florida (2632)
Georgia (567)
Hawaii (5)
Idaho (70)
Illinois (1502)
India (156)
Indiana (786)
Iowa (37)
Japan (783)
Kansas (159)
Kentucky (69)
Louisiana (73)
Maine (99)
Maryland (2049)
Massachusetts (12572)
Michigan (476)
Minnesota (954)
Mississippi (8)
Missouri (190)
Montana (38)
Nebraska (31)
Nevada (205)
New Hampshire (94)
New Jersey (4601)
New Mexico (38)
New York (4525)
North Carolina (2250)
North Dakota (14)
Northern California (8875)
Ohio (542)
Oklahoma (32)
Oregon (55)
Pennsylvania (3324)
Puerto Rico (38)
Rhode Island (66)
South America (1674)
South Carolina (105)
South Dakota (2)
Southern California (6925)
Tennessee (287)
Texas (2891)
United States (61578)
Utah (527)
Vermont (2)
Virginia (436)
Washington D.C. (89)
Washington State (1387)
West Virginia (4)
Wisconsin (200)
Wyoming (6)
898,145 Results for "cell culture company c3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Theralase(R) Closes C$3.6 Million Brokered Financing
August 24, 2026
·
8 min read
Press Releases
One04 Therapeutics presents positive interim Phase 1 data for CPV-104 in C3 glomerulopathy in ASN Kidney Week late-breaker
October 22, 2026
·
5 min read
Press Releases
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
October 6, 2026
·
3 min read
Press Releases
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
July 23, 2026
·
2 min read
Press Releases
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
September 17, 2026
·
15 min read
Press Releases
Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
July 10, 2026
·
5 min read
Press Releases
Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G
May 4, 2026
·
4 min read
Press Releases
Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
April 10, 2026
·
5 min read
Press Releases
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
March 27, 2026
·
3 min read
Press Releases
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
June 3, 2026
·
4 min read
1 of 89,815
Next